Inclusion Criteria:
  -  Willing and able to provide written informed consent
  -  History of histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
  -  Patients with metastatic castration-sensitive (CSPC) or castration-resistant prostate cancer (CRPC) with evidence of metastatic disease on conventional imaging with CT or bone scan.
  -  Prior docetaxel-based chemotherapy is permitted
  -  Documented metastatic prostate cancer progression as assessed by the treating oncologist with either one or both of the following and has not initiated a new therapy after determination of progression: Rising PSA over a minimum 1-week interval and/or radiographic progression in soft tissue and bone metastases (combination of bony and soft tissue metastases)
  -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
Exclusion Criteria:
  -  Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  -  Administered a radioisotope ≤5 physical half-lives prior to the date of study PET/CT
  -  Administered IV X-ray contrast medium ≤24 hours prior to the date of study PET/CT
  -  Administered oral contrast medium ≤120 hours prior to the date of study PET/CT
  -  Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study